GlobalData on MSN1d
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...
Hosted on MSN1d
Access questions hang over Gilead's HIV shot
A new, long-acting shot to prevent HIV could represent a turning point in efforts to reduce cases around the world — if ...
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...
BMJ2d
Gilead to license generic lenacapavir for HIV prophylaxis in 120 lower income countries
Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...
Gilead strikes deal to rush HIV prevention drug to countries most in need
Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...
STAT7d
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
Buy Rating Affirmed: Gilead’s Breakthrough HIV Prevention and Promising Long-Acting Treatments
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
Managed Healthcare Executive5d
Gilead to Distribute Lenacapavir in Top HIV Countries, Critics Unhappy
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
unaids7d
UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...